Top

Published in:

01-03-2021 | Original Research

MicroRNA-196a-5p in Extracellular Vesicles Secreted from Myoblasts Suppresses Osteoclast-like Cell Formation in Mouse Cells

Authors: Yoshimasa Takafuji, Kohei Tatsumi, Naoyuki Kawao, Kiyotaka Okada, Masafumi Muratani, Hiroshi Kaji

Published in: Calcified Tissue International | Issue 3/2021

Abstract

Muscle/bone interaction has been recently noted. Extracellular vesicles (EVs) play a vital role in physiological and pathophysiological processes by transferring microRNA (miRNA) to distant tissues. We previously reported that EVs secreted from C2C12 myoblasts (Myo-EVs) suppress osteoclast differentiation. In the present study, we identified 4 miRNAs in Myo-EVs that suppressed osteoclast-like cell formation in Raw264.7 cells using small RNA sequencing analysis. Among them, miR-196a-5p expression was higher in C2C12 cells compared to mouse osteoblasts and bone marrow cells. Transfection of miR-196a-5p mimic suppressed the mRNA levels of osteoclast-related genes and mitochondrial energy metabolism induced by receptor activator of nuclear factor-κB ligand in Raw264.7 cells. In contrast, miR-196a-5p mimic enhanced osteoblastic differentiation in ST-2 cells and MC3T3-E1 cells. In conclusion, we demonstrated that miR-196-5p suppresses osteoclast-like cell formation and mitochondrial energy metabolism in mouse cells, suggesting that it might be a crucial factor for muscle/bone interaction via EVs.

Available only for authorised users

Kawao N, Kaji H (2015) Interactions between muscle tissues and bone metabolism. J Cell Biochem 116(5):687–695. https://doi.org/10.1002/jcb.25040CrossRefPubMed

Kaji H (2016) Effects of myokines on bone. Bonekey Rep 5:826. https://doi.org/10.1038/bonekey.2016.48CrossRefPubMedPubMedCentral

Ikebuchi Y, Aoki S, Honma M, Hayashi M, Sugamori Y, Khan M, Kariya Y, Kato G, Tabata Y, Penninger JM, Udagawa N, Aoki K, Suzuki H (2018) Coupling of bone resorption and formation by RANKL reverse signalling. Nature 561(7722):195–200. https://doi.org/10.1038/s41586-018-0482-7CrossRefPubMed

Cui YZ, Luan J, Li HY, Zhou XY, Han JX (2016) Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. Febs Lett 590(1):185–192. https://doi.org/10.1002/1873-3468.12024CrossRefPubMed

Li Q, Huang QP, Wang YL, Huang QS (2018) Extracellular vesicle-mediated bone metabolism in the bone microenvironment. J Bone Miner Metab 36(1):1–11. https://doi.org/10.1007/s00774-017-0860-5CrossRefPubMed

Sun WJ, Zhao CY, Li YH, Wang L, Nie GJ, Peng J, Wang AY, Zhang PF, Tian WM, Li Q, Song JP, Wang C, Xu XL, Tian YH, Zhao DS, Xu Z, Zhong GH, Han BX, Ling SK, Chang YZ, Li YX (2016) Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. https://doi.org/10.1038/celldisc.2016.15CrossRefPubMedPubMedCentral

Takafuji Y, Tatsumi K, Ishida M, Kawao N, Okada K, Kaji H (2020) Extracellular vesicles secreted from mouse muscle cells suppress osteoclast formation: roles of mitochondrial energy metabolism. Bone. https://doi.org/10.1016/j.bone.2020.115298CrossRefPubMed

Cheng M, Yang JJ, Zhao XQ, Zhang E, Zeng QT, Yu Y, Yang L, Wu BW, Yi GW, Mao XB, Huang K, Dong NG, Xie M, Limdi NA, Prabhu SD, Zhang JY, Qin GJ (2019) Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. Nat Commun 10:959. https://doi.org/10.1038/s41467-019-08895-7CrossRefPubMedPubMedCentral

Huan J, Hornick NI, Shurtleff MJ, Skinner AM, Goloviznina NA, Roberts CT Jr, Kurre P (2013) RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res 73(2):918–929. https://doi.org/10.1158/0008-5472.CAN-12-2184CrossRefPubMed

10.

Fang SJ, Deng Y, Gu P, Fan XQ (2015) MicroRNAs regulate bone development and regeneration. Int J Mol Sci 16(4):8227–8253. https://doi.org/10.3390/ijms16048227CrossRefPubMedPubMedCentral

11.

Zhao X, Xu D, Li Y, Zhang J, Liu T, Ji Y, Wang J, Zhou G, Xie X (2014) MicroRNAs regulate bone metabolism. J Bone Miner Metab 32(3):221–231. https://doi.org/10.1007/s00774-013-0537-7CrossRefPubMed

12.

Zhang Y, Xie RL, Gordon J, LeBlanc K, Stein JL, Lian JB, van Wijnen AJ, Stein GS (2012) Control of mesenchymal lineage progression by MicroRNAs targeting skeletal gene regulators Trps1 and Runx2. J Biol Chem 287(26):21926–21935. https://doi.org/10.1074/jbc.M112.340398CrossRefPubMedPubMedCentral

13.

Lozano C, Duroux-Richard I, Firat H, Schordan E, Apparailly F (2019) MicroRNAs : key regulators to understand osteoclast differentiation? Front Immunol 10:375. https://doi.org/10.3389/fimmu.2019.00375CrossRefPubMedPubMedCentral

14.

Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B (2018) Treating cancer with microRNA replacement therapy: a literature review. J Cell Physiol 233(8):5574–5588. https://doi.org/10.1002/jcp.26514CrossRefPubMed

15.

Ai GH, Meng M, Wang L, Shao XW, Li Y, Cheng JJ, Tong XW, Cheng ZP (2019) MicroRNA-196a promotes osteogenic differentiation and inhibit adipogenic differentiation of adipose stem cells via regulating beta-catenin pathway. Am J Transl Res 11(5):3081–3091PubMedPubMedCentral

16.

Hou T, Ou J, Zhao X, Huang X, Huang Y, Zhang Y (2014) MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27(Kip1). Brit J Cancer 110(5):1260–1268. https://doi.org/10.1038/bjc.2013.829CrossRefPubMed

17.

Takafuji Y, Hori M, Mizuno T, Harada-Shiba M (2019) Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in Ldlr(-/-) mice. Cardiovasc Res 115(6):1041–1051. https://doi.org/10.1093/cvr/cvy271CrossRefPubMed

18.

Takafuji Y, Tatsumi K, Ishida M, Kawao N, Okada K, Matsuo O, Kaji H (2019) Plasminogen activator inhibitor-1 deficiency suppresses osteoblastic differentiation of mesenchymal stem cells in mice. J Cell Physiol 234(6):9687–9697. https://doi.org/10.1002/jcp.27655CrossRefPubMed

19.

Kawao N, Tamura Y, Okumoto K, Yano M, Okada K, Matsuo O, Kaji H (2013) Plasminogen plays a crucial role in bone repair. J Bone Miner Res 28(7):1561–1574. https://doi.org/10.1002/jbmr.1921CrossRefPubMed

20.

Kim K, Kim JH, Kim I, Lee J, Seong S, Park YW, Kim N (2015) MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol Cells 38(1):75–80. https://doi.org/10.14348/molcells.2015.2241CrossRefPubMed

21.

Ishii K, Fumoto T, Iwai K, Takeshita S, Ito M, Shimohata N, Aburatani H, Taketani S, Lelliott CJ, Vidal-Puig A, Ikeda K (2009) Coordination of PGC-1 beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15(3):259–266. https://doi.org/10.1038/nm.1910CrossRefPubMed

22.

Yu FY, Xie CQ, Sun JT, Peng W, Huang XW (2018) Overexpressed miR-145 inhibits osteoclastogenesis in RANKL-induced bone marrow-derived macrophages and ovariectomized mice by regulation of Smad3. Life Sci 202:11–20. https://doi.org/10.1016/j.lfs.2018.03.042CrossRefPubMed

23.

Li GW, Bu JY, Zhu YX, Xiao XY, Liang ZB, Zhang RK (2015) Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9. Int J Clin Exp Patho 8(12):15684–15695

24.

Yin YR, Tang L, Chen JY, Lu XB (2017) MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling. Am J Transl Res 9(12):5743–5753PubMedPubMedCentral

25.

Zhang J, Zhao HY, Chen JP, Xia B, Jin YM, Wei W, Shen JJ, Huang YZ (2012) Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. Febs Lett 586(19):3255–3262. https://doi.org/10.1016/j.febslet.2012.06.047CrossRefPubMed

26.

Kim YJ, Bae SW, Yu SS, Bae YC, Jung JS (2009) miR-196a regulates proliferation and osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res 24(5):816–825. https://doi.org/10.1359/jbmr.081230CrossRefPubMed

27.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6):889–901. https://doi.org/10.1016/S1534-5807(02)00369-6CrossRefPubMed

28.

Zhao BH, Takami M, Yamada A, Wang XG, Koga T, Hu XY, Tamura T, Ozato K, Choi YW, Ivashkiv LB, Takayanagi H, Kamijo R (2009) Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 15(9):1066–1071. https://doi.org/10.1038/nm.2007CrossRefPubMedPubMedCentral

29.

Franceschetti T, Kessler CB, Lee SK, Delany AM (2013) miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration. J Biol Chem 288(46):33347–33360. https://doi.org/10.1074/jbc.M113.484568CrossRefPubMedPubMedCentral

30.

Krzeszinski JY, Wei W, Huynh H, Jin ZX, Wang XD, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YH (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512(7515):431–435. https://doi.org/10.1038/nature13375CrossRefPubMed

31.

Zhou L, Song HY, Gao LL, Yang LY, Mu S, Fu Q (2019) MicroRNA-100-5p inhibits osteoclastogenesis and bone resorption by regulating fibroblast growth factor 21. Int J Mol Med 43(2):727–738. https://doi.org/10.3892/ijmm.2018.4017CrossRefPubMed

32.

Li Y, Zhang MX, Chen HJ, Dong Z, Ganapathy V, Thangaraju M, Huang SA (2010) Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res 70(20):7894–7904. https://doi.org/10.1158/0008-5472CrossRefPubMedPubMedCentral

33.

Tsai MM, Wang CS, Tsai CY, Huang CG, Lee KF, Huang HW, Lin YH, Chi HC, Kuo LM, Lu PH, Lin KH (2016) Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer. Eur J Cancer 64:137–148. https://doi.org/10.1016/j.ejca.2016.05.007CrossRefPubMed

34.

Ge J, Chen ZH, Li RX, Lu TL, Xiao GF (2014) Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int 14:128. https://doi.org/10.1186/s12935-014-0128-2CrossRefPubMedPubMedCentral

35.

Suh YE, Raulf N, Gaken J, Lawler K, Urbano TG, Bullenkamp J, Gobeil S, Huot J, Odell E, Tavassoli M (2015) MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. Int J Cancer 137(5):1021–1034. https://doi.org/10.1002/ijc.29397CrossRefPubMed

36.

Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, Yang JS, Yin DD, Liu ZL, Zhou J, Liu ZJ, De W, Wang ZX (2012) MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. Bmc Cancer 12:348. https://doi.org/10.1186/1471-2407-12-348CrossRefPubMedPubMedCentral

37.

Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hebuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P (2011) A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat Genet 43(3):242–245. https://doi.org/10.1038/ng.762CrossRefPubMed

38.

Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AWS, Chen CM, Yang SH (2013) miR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 93(2):306–312. https://doi.org/10.1016/j.ajhg.2013.05.025CrossRefPubMedPubMedCentral

39.

Her LS, Mao SH, Chang CY, Cheng PH, Chang YF, Yang HI, Chen CM, Yang SH (2017) miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in huntington’s disease. Theranostics 7(9):2452–2462. https://doi.org/10.7150/thno.18813CrossRefPubMedPubMedCentral

40.

Candini O, Spano C, Murgia A, Grisendi G, Veronesi E, Piccinno MS, Ferracin M, Negrini M, Giacobbi F, Bambi F, Horwitz EM, Conte P, Paolucci P, Dominici M (2015) Mesenchymal progenitors aging highlights a miR-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis. Stem Cells 33(3):939–950. https://doi.org/10.1002/stem.1897CrossRefPubMed

41.

Xu Q, Cui YZ, Luan J, Zhou XY, Li HY, Han JX (2018) Exosomes from C2C12 myoblasts enhance osteogenic differentiation of MC3T3-E1 pre-osteoblasts by delivering miR-27a-3p. Biochem Bioph Res Co 498(1):32–37. https://doi.org/10.1016/j.bbrc.2018.02.144CrossRef

42.

Esen E, Lee SY, Wice BM, Long FX (2015) PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling. J Bone Miner Res 30(11):2137–2137. https://doi.org/10.1002/jbmr.2714CrossRefPubMed

43.

Liu ZB, Solesio ME, Schaffler MB, Frikha-Benayed D, Rosen CJ, Werner H, Kopchick JJ, Pavlov EV, Abramov AY, Yakar S (2019) Mitochondrial function is compromised in cortical bone osteocytes of long-lived growth hormone receptor null mice. J Bone Miner Res 34(1):106–122. https://doi.org/10.1002/jbmr.3573CrossRefPubMed

Title: MicroRNA-196a-5p in Extracellular Vesicles Secreted from Myoblasts Suppresses Osteoclast-like Cell Formation in Mouse Cells
Authors: Yoshimasa Takafuji
Kohei Tatsumi
Naoyuki Kawao
Kiyotaka Okada
Masafumi Muratani
Hiroshi Kaji
Publication date: 01-03-2021
Publisher: Springer US
Published in: Calcified Tissue International / Issue 3/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-020-00772-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

High-Resolution Cone-Beam Computed Tomography is a Fast and Promising Technique to Quantify Bone Microstructure and Mechanics of the Distal Radius

Genetically Predicted Sex Hormone-Binding Globulin and Bone Mineral Density: A Mendelian Randomization Study

Intermittent PTH Administration Increases Bone-Specific Blood Vessels and Surrounding Stromal Cells in Murine Long Bones

Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA)

Relationships Between Level and Change in Sarcopenia and Other Body Composition Components and Adverse Health Outcomes: Findings from the Health, Aging, and Body Composition Study

Genotype–Phenotype Associations in 72 Adults with Suspected ALPL-Associated Hypophosphatasia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials